Brigatinib (AP26113) Efficacy and Safety in ALK plus NSCLC: Phase 1/2 Trial Results

被引：0
|
作者：
Gettinger, Scott N. [1 ]
Bazhenova, Lyudmila [2 ]
Salgia, Ravi [3 ]
Langer, Corey J. [4 ]
Gold, Kathryn A. [5 ]
Rosell, Rafael [6 ,7 ]
Shaw, Alice [8 ]
Weiss, Glen J. [9 ]
Dorer, David J. [10 ]
Rivera, Victor M. [10 ]
Conlan, Maureen G. [10 ]
Kerstein, David [10 ]
Camidge, Ross [11 ]
机构：
[1] Yale Canc Ctr, New Haven, CT USA
[2] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[3] Univ Chicago Med, Chicago, IL USA
[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Dexeus Univ Inst, Barcelona, Spain
[7] Catalan Inst Oncol, Barcelona, Spain
[8] Massachusetts Gen Hosp, Boston, MA 02114 USA
[9] Canc Treatment Ctr Amer, Goodyear, AZ USA
[10] Ariad Pharmaceut Inc, Cambridge, MA USA
[11] Univ Colorado, Ctr Canc, Aurora, CO USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
NSCLC; TKI; brigatinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ORAL33.06
引用
收藏
页码：S238 / S239
页数：2
相关论文
共 50 条
  • [31] Brigatinib vs crizotinib in ALK TKI-naive ALK plus NSCLC: final results from ALTA-1L
    Popat, Sanjay
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James
    Han, Ji-Youn
    Hochmair, Maximilian
    Lee, Ki Hyeong
    Delmonte, Angelo
    Garcia Campelo, Maria
    Kim, Dong-Wan
    Griesinger, Frank
    Felip, Enriqueta
    Califano, Raffaele
    Spira, Alexander
    Gettinger, Scott
    Tiseo, Marcello
    Lin, Huamao
    Liu, Yuyin
    Vranceanu, Florin
    Camidge, D.
    LUNG CANCER, 2022, 165 : S27 - S28
  • [32] Brigatinib (BRG) in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Updates from a phase 1/2 trial.
    Bazhenova, Lyudmila
    Gettinger, Scott N.
    Langer, Corey J.
    Salgia, Ravi
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice Tsang
    Weiss, Glen J.
    Haney, Jeff
    Rivera, Victor M.
    Kerstein, David
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.
    Camidge, D. Ross
    Bazhenova, Lyudmila
    Salgia, Ravi
    Weiss, Glen J.
    Langer, Corey J.
    Shaw, Alice Tsang
    Narasimhan, Narayana I.
    Dorer, David J.
    Rivera, Victor M.
    Zhang, Joshua
    Clackson, Tim
    Haluska, Frank G.
    Gettinger, Scott N.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)
    Ou, Sai-Hong Ignatius
    Nishio, Makoto
    Ahn, Myung-Ju
    Mok, Tony
    Barlesi, Fabrice
    Zhou, Caicun
    Felip, Enriqueta
    de Marinis, Filippo
    Kim, Sang-We
    Perol, Maurice
    Liu, Geoffrey
    Migliorino, Maria Rita
    Kim, Dong-Wan
    Novello, Silvia
    Bearz, Alessandra
    Garrido, Pilar
    Mazieres, Julien
    Morabito, Alessandro
    Lin, Huamao M.
    Yang, Hui
    Niu, Huifeng
    Zhang, Pingkuan
    Kim, Edward S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (12) : 1404 - 1414
  • [35] Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK plus NSCLC: First Report of a Phase 3 Trial (ALTA-1L)
    Camidge, R.
    Kim, H. R.
    Ahn, M.
    Yang, J. C.
    Han, J.
    Lee, J.
    Hochmair, M.
    Li, J. Y.
    Chang, G.
    Lee, K.
    Gridelli, C.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D.
    Bearz, A.
    Griesinger, F.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Haney, J.
    Kerstein, D.
    Popat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S184 - S185
  • [36] Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK plus NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials
    Camidge, D. Ross
    Sugawara, Shunichi
    Kondo, Masashi
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James C. H.
    Han, Ji-Youn
    Hochmair, Maximilian J.
    Lee, Ki Hyeong
    Delmonte, Angelo
    Kudou, Kentarou
    Asato, Takayuki
    Hupf, Bradley
    Vranceanu, Florin
    Fram, Robert J.
    Ohe, Yuichiro
    Popat, Sanjay
    LUNG CANCER, 2025, 201
  • [37] Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Final results of the Phase 1/2 and Phase 2 (ALTA) trials
    Huber, R.
    Gettinger, S.
    Kim, D. -W
    Bazhenova, L.
    Hansen, K.
    Tiseo, M.
    Langer, C.
    Paz-Ares Rodriguez, L.
    West, H.
    Reckamp, K.
    Weiss, G.
    Smit, E.
    Hochmair, M.
    Kim, S. -W
    Ahn, M. -J
    Kim, E.
    Groen, H.
    Pye, J.
    Vranceanu, F.
    Camidge, D. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 4 - 5
  • [38] Brigatinib in ALK plus NSCLC pts with intracranial CNS metastases in 2 clinical trials
    Tiseo, M.
    Huber, R. M.
    Hochmair, M. J.
    Bazhenova, L. A.
    Ou, S-H. I.
    Reichmann, W.
    Haney, J.
    Kerstein, D.
    Camidge, D. R.
    Gettinger, S. N.
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] Brigatinib in crizotinib-refractory ALK1 NSCLC: Updates from the pivotal randomized phase 2 Trial (ALTA)
    Hochmair, M. J.
    Tiseo, M.
    Reckamp, K. L.
    West, H. L.
    Groen, H. J.
    Langer, C. J.
    Reichmann, W.
    Kerstein, D.
    Kim, D-W.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
    Camidge, D. Ross
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James C. H.
    Han, Ji-Youn
    Hochmair, Maximilian J.
    Lee, Ki Hyeong
    Delmonte, Angelo
    Campelo, Maria Rosario Garcia
    Kim, Dong-Wan
    Griesinger, Frank
    Felip, Enriqueta
    Califano, Raffaele
    Spira, Alexander I.
    Gettinger, Scott N.
    Tiseo, Marcello
    Lin, Huamao M.
    Liu, Yuyin
    Vranceanu, Florin
    Niu, Huifeng
    Zhang, Pingkuan
    Popat, Sanjay
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 2091 - 2108
12345